Aljinomics Unveils Strategy to Strengthen Global Patent Portfolio Through IP-Based R&D
Aljinomics, a company specializing in the development of ribonucleic acid (RNA)-based gene therapies, is systematically building a global patent portfolio for its proprietary platform technologies, further strengthening its technological barriers in the next-generation bio market.
Aljinomics announced that on the 4th it held a roundtable meeting during a visit by the Office of Intellectual Property, where they discussed the current status of securing core technologies in the advanced bio sector and strategies to enhance competitiveness in the global market.
On the 4th, officials including Kim Yongsun, Head of Intellectual Property (third from left), and Lee Seonguk, CEO of Aljinomics (fourth from left), who visited Aljinomics, an RNA gene therapy developer based in Seongnam, Gyeonggi Province, are taking a commemorative photo. Aljinomics
View original imageSince 2022, Aljinomics has participated three times in the Office of Intellectual Property’s “Intellectual Property-Research and Development (IP-R&D) Strategy Support Program,” through which it has built its patent strategy. Based on its R&D achievements, the company drew attention as an exemplary case by completing a listing in December under the “Ultra-Gap Technology Special Listing” track. It also attracted interest as the first advanced bio company visited after the Korean Intellectual Property Office was upgraded to the Office of Intellectual Property in October.
Aljinomics holds 73 domestic and overseas patents for its core platforms, the “Trans-splicing Ribozyme” RNA replacement enzyme platform and the “Circular RNA” platform. The company’s patent strategy has focused on establishing an “IP-R&D linked strategy” that secures market exclusivity from the early stages of development, and it has been filing Patent Cooperation Treaty (PCT) applications and securing broad rights for each pipeline that replaces disease-causing RNA with normal RNA. The substance patent for its anticancer gene therapy “RZ-001” has been filed in four major countries including Korea, and has already been registered in Korea, the United States, and Japan. Patents for its candidate substances under development as treatments for Alzheimer’s disease and retinitis pigmentosa have also either been registered or are in the process of being filed in major overseas countries including the United States.
Recently, the company completed patent registrations in Korea (two cases), the United States, Japan, and Australia for self-circularizing RNA constructs that overcome the limitations of existing circular RNA technologies. This patent portfolio constitutes fundamental patents that are broadly applicable to trans-splicing ribozyme-based substances and is expected to serve as a technological barrier that effectively blocks competitors’ entry into the market.
On the strength of such intellectual property rights, Aljinomics was recognized in 2024 by the Ministry of Science and ICT as the first company in the “National Strategic Technologies” program, and it has been internalizing IP strategy from the R&D planning stage and linking it through to market entry. As the Office of Intellectual Property recently announced that it would expand the scope of its accelerated examination program to advanced technologies, including artificial intelligence and bio, synergies are expected in the form of earlier acquisition of patent rights for advanced bio technologies and shorter examination periods.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Aljinomics official stated, “In the advanced bio field, intellectual property rights are an essential element for proving the maturity of a technology and moving toward global commercialization,” adding, “Through IP-based R&D, we will continue to expand a strategic patent network that encompasses the entirety of Aljinomics’ core RNA platform technologies.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.